2008/06/18     Shanghai Genomics announced positive results of the phase II trial of F647 for Idiopathic Pulmonary Fibrosis in a randomized, double-blind, placebo-controlled, and multi-center clinical trial. A total of 72 patients were enrolled. The trial results demonstrated that primary end points are improved with statistical significance. F647 was well tolerated by patients also. At the same time, F647 is also in phase II study for the prevention and therapy of Radiation Pneumonitis.

2008/05/29    Dr. Ying Luo was invited to give a speech a the Global R&D Congress at Washington DC, USA. He presented the business model of Shanghai Genomics and future direction of drug development in China.

2008/05/16     Shanghai Genomics employees and GNI employees in Tokyo,voluntarily donated cash and "Gu Bang" orthopedics products to the RedCross of Shanghai for earthquake victims of Sichuan province. The totalvalue of the donation is approximately RMB 233,500 (JPY3.5 million or USD33,000).

2008/04/01    Dr. Ying Luo chaired the afternoon session of the IBC China 2008 Pharmaceutical R&D Summit. Nearly 400 delegates from worldwide pharmaceutical industry attended the conference.

2008/01/23    Two of Shanghai Genomics research publications were designated "Excellent Scientific Papers" by Shanghai’s Pudong New Area.  Both papers were published by the Proceedings of the National Academy of Sciences of the United States of America (PNAS), one of the world's leading multidisciplinary scientific serials.  Dr. Jun Wu, the Chief Scientific Officer of GNI, Ltd. and Shanghai Genomics, is the lead and corresponding author for both papers. The awardees were selected from more than five hundred papers in many scientific fields.

2008/01/18    Shanghai Genomics’ high through-put drug target screening platform, which is based on the company's key technology and expertise, was awarded the "Science and Technology Award of the Year" by the municipal government of Shanghai.  Using this platform, Shanghai Genomics performs large-scale screening for cancer and inflammation related genes and identifies promising drug targets.

© 2007~2018 shanghaigenomics.com. All rights reserved. Shanghai ICP 08017875